Quantitative Proteomic Analysis Reveals the Deregulation of Nicotinamide Adenine Dinucleotide Metabolism and CD38 in Inflammatory Bowel Disease

Abstract EN

Inflammatory bowel disease (IBD) has become a major health challenge worldwide.

However, the precise etiological and pathophysiological factors involved in IBD remain unclear.

Proteomics can be used for large-scale protein identification analysis.

In the current study, using tandem mass tag- (TMT-) based shotgun proteomics, proteomic differences between intestinal tissue from health controls, patients with Crohn’s disease (CD), and patients with ulcerative colitis (UC) were compared.

Proteins with fold change >2 or <0.5 and P value < 0.05 between groups were considered differentially expressed.

ProteinAtlas was used to analyze the tissue specificity of differentially expressed proteins (DEPs).

Reactome pathway analysis was applied to cluster functional pathways.

A total of 4786 proteins were identified, with 59 proteins showing higher levels and 43 showing lower levels in patients with IBD than in controls.

Seventeen proteins, including angiotensin converting enzyme 2 (ACE2) and angiotensin converting enzyme 1 (ACE), showed higher levels in CD than in UC.

Several novel proteins such as CD38, chitinase 3-like 1 (CHI3L1), olfactomedin 4 (OLFM4), and intelectin 1 were screened out between patients with IBD and controls.

When proteins with fold change >1.2 or <0.84 and P value < 0.05 between groups were considered differentially expressed, the expression of 10 proteins, including CD38, involved in the nicotinamide adenine dinucleotide (NAD) metabolism and signaling pathway showed significant changes in IBD.

Using the NCBI GEO database, we confirmed increased CD38 mRNA expression in patients with UC and in mouse colitis models.

Protein CD38 expression was higher in CD and UC than in normal controls.

CD38 expression was higher in inflamed tissues than in noninflamed tissues, and CD38 was located in F4/80-positive cells.

Our study may provide novel insights into the molecular pathogenesis of IBD.

Further studies are required on the role of NAD metabolism and CD38 in intestinal inflammation.